Skip to main content
Third Harmonic Logo
  • About us
    • Overview
    • Our values
    • Leadership team
    • Board of directors
  • Our science
    • The opportunity
    • Publications
  • Pipeline
    • Overview
  • Investors & media
    • Overview
    • Press releases
    • Events & presentations
    • Publications
    • Analyst Coverage
    • Governance
    • SEC filings
    • Financial results
  • Careers
    • Overview
    • Open positions
Publications
02/24/2023 | American Association of Allergy, Asthma, and Immunology
First-in-Human Safety, Pharmacokinetics and Pharmacodynamics of THB001: An Orally Available, Potent and Highly Selective Small Molecule Inhibitor of Wild Type KIT Receptor Tyrosine Kinase
02/24/2023 | American Association of Allergy, Asthma, and Immunology
Efficacy of THB001, a Potent and Selective Oral Small Molecule Inhibitor of Wild Type KIT Receptor Tyrosine Kinase, in a Rat Passive Cutaneous Anaphylaxis Model
Contact Us
info@thirdharmonicbio.com
1700 Montgomery Street, Suite #210
San Francisco, CA 94111
Twitter LinkedIn
  • Privacy policy
  • Terms of use

© Third Harmonic Bio